Roche's sBLA for Tecentriq-Abraxane Combo Accepted by FDA

A pen notebook and calculator laying on top of sheets of paper
Credit: Shutterstock photo

Swiss oncology major RocheRHHBY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for immuno-oncology drug, Tecentriq.

The sBLA seeks to get FDA approval for Tecentriq in combination with Celgene Corporation's CELG Abraxane and carboplatin for the initial (first-line) treatment of patients suffering from metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations.

A decision from the FDA is expected by Sep 2, 2019.

The sBLA is based on positive results from the phase III IMpower130 study, which met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) in the first-line treatment of metastatic non-squamous NSCLC.

We remind investors that Tecentriq is already approved in the Unites States for the treatment of patients suffering from metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. In December 2018, the FDA also approved Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) for the first-line treatment of people with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.

The drug is also approved for certain types of untreated or previously treated metastatic urothelial carcinoma (mUC).

Shares of Roche have gained 10.9% in the past six months, outperforming the industry's growth of 4.5%.

Roche is working to expand the drug's label further. The company currently has nine phase III studies evaluating Tecentriq alone or in combination with other drugs for lung cancer.Tecentriq sales came in at CHF 524 million in the first nine months of 2018, up 49%. A label expansion of the drug in the first-line NSCLC market will further boost sales, given the potential of the market.

However, competition is stiff in the first-line NSCLC market. Merck's MRK Keytruda is already approved for the first-line treatment of NSCLC.

Bristol-Myers Squibb Company's BMY Opdivo is also in the race for the first-line NSCLC treatment. However, the FDA extended the review period of the company's application by three months and set a target action date of May 20, 2019.

Zacks Rank

Roche currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Get Free Report

Merck & Co., Inc. (MRK): Free Stock Analysis Report

Celgene Corporation (CELG): Get Free Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More